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1. Abbreviations: 
2-D  two-dimensional 
2-DPD  two-dimensional power Doppler 
2-DCD  two-dimensional color Doppler 
3-D  three-dimensional 
3-DPD  three-dimensional power Doppler 
AC  abdominal circumference 
AD  abdominal diameter 
AFI  amniotic fluid index 
AOR  adjusted odds ratio 
BMI  body mass index (kg/m2) 
BPD  biparietal diameter 
CI  confidence interval 
D  minimum telediastolic velocity (cm/s) 
DM  diabetes mellitus 
EFW  estimated fetal weight 
FGF-2  fibroblast growth factor-2 
FI  flow index 
FL  femur length 
GA  gestational age 
GDM  gestational diabetes mellitus 
HC  head circumference 
HIV  human immunodeficiency virus 
HRE  hypoxia-inducible factor responsive element 
ICC  intra-class correlation coefficient 
IGF  insulin-like growth factors 
IGF-1  insulin-like growth factor 1 
IGF-2  insulin-like growth factor 2 
IUGR  intrauterine growth restriction 
EDTA-Na2  disodium ethylenediaminetetraacetate dihydrate 
OGTT  oral glucose tolerance test 
PD  power Doppler 
PVS  placental volume sampling 
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GDM  gestational diabetes mellitus 
PI  pulsatility index 
RI  resistance index 
S  maximum systolic velocity (cm/s) 
S.D.  standard deviation 
SGA  small for gestational age 
T1DM  diabetes mellitus type 1 
VEGF  vascular endothelial growth factor 
VFI  vascularisation flow index 
VI  vascularisation index (%) 
VOCAL  virtual organ computer-aided analysis 
vs  versus  
wk  week 
ys  years 
WHO  World Health Organisation 
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2.    Summary 
A prospective study was carried out in order to examine placental vascularisation using 3-
dimensional power Doppler (3-DPD) technique with Virtual Organ Computer-aided Analysis 
(VOCAL) program in the second and third trimester of pregnancies complicated by diabetes 
mellitus (DM) and intrauterine growth restriction (IUGR) and to compare them with those of 
the normal controls. 
Conventional two-dimensional (2-D) ultrasound has been widely used for the 
evaluation of the placenta during pregnancy. This 2-D ultrasound evaluation includes the 
morphology, anatomy, location, implantation, anomaly, size, color/power and pulsed Doppler 
ultrasound assessment of the placenta. The 2-D ultrasound is useful to assess normal and 
abnormal placentas in most pregnancies. The three-dimensional (3-D) reconstruction of the 
placenta gives information about 3-D placental vasculature and placental blood flow. The 
quantitative 3-DPD histogram analysis by VOCAL program provides more details concerning 
qualitative assessments of the vascularisation and blood flow of the placenta. 3-DPD 
ultrasound examination can depict intraplacental vessel characteristics such as coiling of 
vessels, branching and changes in lumen by subjective assessment. We analyzed the alteration 
in vascularisation by an objective evaluation method using the VOCAL program. 
A consecutive series of pregnant women was recruited at the maternity outpatient 
clinic between 2011 and 2013 at Department of Obstetrics and Gynecology, Szeged, Hungary. 
a, In the GDM/T1DM study: pregnancies complicated by gestational diabetes mellitus (GDM) 
(n=56) and diabetes mellitus type-I (T1DM) (n=43) were compared to uncomplicated 
pregnancies (n=113). 
b, In the IUGR study pregnancies were divided into two groups: non-pathological control 
group (n=171) and IUGR group (n=52). 
For 2-D, 3-D and color Doppler examinations Voluson 730 ultrasound equipment (GE 
Medical System, Kretztechnik, Austria) and RAB 2-5 MHz convex transducer were used. The 
vascularisation of placentas was assessed in the second and third trimester of pregnancies 
complicated by GDM/T1DM and IUGR as well as of normal pregnancies using 3-DPD 
technique. For „placental vascular biopsy” we applied the „Mercé-type sonobiopsy” at 
insertion of the umbilical cord, the most vascularised part of the placenta. The stored 3-D 
volume images were analyzed with VOCAL program pertaining to the computer software 4-D 
View (GE Medical Systems, Austria, version 10.4). The VOCAL program calculates 
automatically the indices from gray-scale and color values of the acquired spherical sample. 
The calculated indices were: a) vascularisation index (VI), b) flow index (FI) and c) 
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vascularisation flow index (VFI) of the placenta. The statistical analysis was performed with 
the help of SPSS for Windows 17.0 program. 
 In case of IUGR and diabetic patients, significant deterioration of VI, FI and VFI 
occurred compared to the control group. The 3-DPD indices were not significantly different 
between the two diabetic subgroups. It can be established that all 3-DPD indices were 
constant during the progress of normal pregnancies. Placental vascularisation in pregnancies 
complicated by IUGR is lower even in the first trimester of gestation. In diabetic pregnancies 
despite of the hypervascularisation of villi low placental vascularisation is measured because 
of placental edema. 
In conclusion, 3-DPD assessment of placental vascularisation may provide new 
insights into normal and abnormal fetoplacental hemodynamics. 
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3. Introduction 
The placenta is the organ responsible for the transfer of almost all the nutrients and 
gases between mother and fetus. Thus, the placenta plays a fundamental role. It allows the 
transfer of nutrients and oxygen from the mother to the fetus and the transfer of waste 
products and carbon dioxide back from the fetus to the maternal blood system. The placenta 
plays a pivotal role in excretion of urea, uric acid and creatinine from the fetus to the maternal 
blood. It takes part in immunity, it has endocrine function during pregnancy as well and 
provides a reservoir of blood for the fetus. The human placenta is a highly invasive and 
proliferative structure during the first half of pregnancy. The development and maturation of 
placenta and the maintenance of successful pregnancy are dependent on the proper 
proliferation and differentiation of the villous cytotrophoblast cells into maternal deciduas and 
myometrium in early pregnancy. This process leads to transformation of the spiral arteries 
supplying the intervillous space. These physiological changes alter the vascular supply to a 
low-pressure high-flow system, allowing adequate flow to the developing villous circulation, 
which undergoes progressive arborisation until late pregnancy in the third trimester. 
Consequently, all of the respiratory gases, nutrients, and waste products that are exchanged 
between the material and fetal system are transported via placenta. The importance of 
transplacental exchange in supplying metabolic substrates required for fetal growth is 
apparent and has long been recognized [1, 2]. Fetal growth is the result of complex cascade of 
processes which requires coordination of components within the maternal, placental and fetal 
compartments (see Table 1). Placental dysfunction is known to be a major cause of 
complications during pregnancy, such as intrauterine growth restriction [3, 4]. The alteration 
of the uteroplacental circulation leads to fetal hypoxia. It is followed by circulatory 
redistribution for the sake of substantial organs such as brain, heart and adrenal glands. The 
fetus stops or reduces weight-gain.  
In diabetes mellitus, the placenta undergoes a variety of structural and functional 
changes [5-7]. Their nature and extent depend on a range of variables including the quality of 
glycemic control achieved during the critical periods in placental development, the modality 
of treatment, and the time period of severe deviation from excellent metabolic control of a 
non-diabetic environment. In pregnancies with diabetes, the concentration of insulin in the 
fetoplacental circulation is increased due to hyperglycemia. High concentrations of insulin 
and insulin-like growth factors (IGFs) in maternal serum in pregnancy have been associated 
with high birth-weight in offspring of women both with and without diabetes [8, 9]. In 
pregnancy these factors are synthesized in the placenta and they also regulate placental 
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growth. It is conceivable that there is a relatively larger growth of the placenta than of the 
offspring. 
Pregnancy is a state of requirement of higher amount of oxygen. Women with diabetes 
have an increased prevalence of cardiovascular disease and atherosclerosis [10, 11]. 
Atherosclerosis may impair the oxygenation of the tissues and, in pregnancy, may increase the 
risk of uteroplacental hypoxia. Hypoxia stimulates angiogenesis [12, 13] and it is conceivable 
that uteroplacental hypoxia initiates placental angiogenesis and thereby placental growth [12]. 
The severity of maternal vascular dysfunction is likely to be associated with the duration of 
diabetes. The presence of atherosclerosis is associated with the duration of diabetes [10]. 
Diabetes, independent of type, may also cause low grade inflammation with micro- and 
macrovascular complications associated with hypoxia [11]. Inflammation not only on the 
maternal site but also in the placenta has been reported in diabetic pregnancies, and such 
inflammation may cause placental dysfunction and activate angiogenesis [14]. Large offspring 
may have increased need for oxygen and nutrition and such a need may initiate compensatory 
growth of the placenta. Also, a large placenta in itself may have an increased need for oxygen 
and nutrition. Thus a large placenta is dysfunctional relative to the fetal needs, leading to a 
compensatory placental growth. Histological abnormalities with immature villi are mentioned 
in pregnancies with diabetes [15]. Placental villous immaturity and large placentas have been 
seen in well controlled diabetic pregnancies [16], suggesting that there may be a 
compensatory growth of placenta with immature villi, independent on the maternal glucose 
concentrations. 
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Table 1.  Maternal, fetal and uteroplacental factors responsible for development of IUGR 
I. Maternal factors: 
 
1. General and constitutional factors: 
-age (<20 and >30 years)  -mother’s weight before pregnancy (<50 kg)-
mother’s height (<150cm) 
-mother’s birth weight -ethnic/racial characteristics  
 (e.g. in case of Roma ethnicity in our country) 
 
2. Social and economic situation: 
-no education -dangerous physical work 
-single mother -maternal malnutrition 
 
3. Geographical and climatic relations: 
-sea level (the more its value is, the more frequently IUGR occurs) 
-climatic conditions 
 
4. Toxic substances: 
-smoking, alcohol, caffeine (7-8 coffee/day), drugs 
 
5. Medical treatment of the pregnant woman: 
-tetracyclines -hydantoin anticonvulsants 
-anticoagulants -lithium 
 (Warfarin) 
-folic acid antagonist 
 (aminopterin) 
 
6. Maternal diseases: 
-chronic kidney disease -chronic cardiopulmonary disease 
-preeclampsia -anaemia 
-chronic hypertension -urinary infection 
-maternal hyperinsulinemia -autoimmune diseases  
 (Systemic Lupus Erythematosus) 
 
II.  Fetal factors: 
-fetal sex 
-chromosomal abnormality 
 (autosomal genetic disorders: Down, Edwards, Patau syndromes) 
 (gender dependant genetic disorders: Turner, Multiple X syndrome) 
-genetic syndromes: (bone dysplasia) 
-intrauterine infection 
-multiple pregnancy 
-immunological factor 
-time between pregnancies (weight loss <2  or >6 years) 
 
III. Uteroplacental factors: 
-uterine malformations -tumor (haemangioma) 
-placental anomalies -single umbilical artery (SUA) 
-abnormal localisation of placenta -placental mosaicism 
(placenta previa) 
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3.1. GDM/T1DM 
The placenta fulfils a fundamental role sustaining adequate fetal growth, and it has been 
implicated in fetal growth and has been associated with maternal diabetes. Various 
morphological and functional placental changes can be observed in these pregnancies as well. 
They depend on period in gestation when the diabetic insult manifests itself [17]. In our study 
diabetes mellitus type 1 (T1DM) has been already diagnosed before pregnancy and GDM is 
discovered for the first time during pregnancy. GDM is a pathological condition, in which 
women without previously diagnosed diabetes exhibit high blood glucose levels during 
pregnancy, irrespective of whether it is treated with diet or insulin, which disappears or 
maintains after pregnancy [18, 19]. In addition to these facts, a transient self-limiting state of 
hyperglycemia may occur in pregnancy as a result of maternal endocrine changes. Glucose 
homeostasis is maintained by the balance between insulin, which reduces glucose levels by 
increasing cellular uptake, and other hormones such as glucagon and cortisol, which increase 
glucose production. Carbohydrate intolerance develops often during pregnancy. The placenta 
produces additional cortisol as well as other insulin antagonists such as human placental 
lactogen, progesterone, human chorionic gonadotropin, insulysin, all of which tend to increase 
the maternal glucose level [20]. If the pancreatic B islet cells are unable to produce sufficient 
insulin to balance this increase or if there is maternal insulin resistance, the mother may 
develop a state of hyperglycemia referred to as gestational diabetes [21]. Several risk factors 
are associated with the development of GDM (see Table 2). 
 
Table 2. The most common risk factors which are associated with the development of GDM 
 
 
 
-non-Caucasian women,                                  -former fetal malformation 
-high maternal age (>35 years)                        -intrauterine death 
-obesity (BMI>30kg/m
2
)                                 -habitual abortion 
-familial diabetes                                             -hypertension 
-glycosuria during pregnancy  
-previous birth of a macrosomic (birth weight at the term is ≥4000 grams) 
or a large for gestational age neonate (above the 90 percentile)  
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Excess placental weight in diabetes correlates with antenatal glucose control. The 
increase in tissue mass results from overproduction of extracellular matrix worsened by 
interstitial edema [17]. Villous immaturity and cytotrophoblasts that are more apparent by 
histological investigation, for any given gestational age (GA) are typical in the diabetic 
placenta [17]. The etiology of this cytotrophoblast prominence is unclear, but may relate to 
cytotrophoblast fusion to form syncytiotrophoblast. Basement membranes of the 
syncytiotrophoblast and endothelium are thickened in pre-gestational and GDM and this 
likely reduces villous diffusion capacity for oxygen. Hypervascularisation of the villi is also a 
common finding. In T1DM this secondary feature leads to enhanced longitudinal growth of 
vessels, whereas in GDM vascular branching is increased. The underlying mechanism for 
stimulation of branching or non-branching angiogenesis is unknown (see Figure 2) [17]. 
 
Figure 2. Characteristic changes associated with maternal diabetes in placental villi at term 
of pregnancy [17] 
 
 
 
 The enlargement of the vascular surface and also the placental surface area of 
exchange may be counterintuitive in a situation of maternal nutritional oversupply. However 
this may reflect to a response to inadequate oxygen supply to the fetus where fetal hypoxia is 
linked to polycythemia and elevated cord blood erythropoietin levels. Elevated maternal 
HbA1c levels with higher oxygen affinity, reduced uteroplacental blood flow, and a longer 
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maternal-to-fetal diffusion distance may diminish oxygen supply. At the same time fetal 
hyperinsulinemia stimulates aerobic metabolism, thus increasing oxygen demand.  Low-fetal-
oxygen levels may induce placental expression of pro-angiogenic factors, such as fibroblast 
growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF) [17]. The FGF-2, 
VEGF, leptin, insulin and insulin-like growth factors 1 and 2 (IGF1 and 2) stimulate 
mitogenic, angiogenic and invasive process [17].  The expansion of the vascular tree is also 
paralleled by an increase in capillary volume and diameter. This dilatation of the placental 
capillaries may again result from fetal hypoxia, because low oxygen is known to up-regulate 
eNOS expression via hypoxia-inducible factor responsive elements (HREs) enabling the 
production of higher levels of vasodilator NO (see Figure 3) [17]. 
 
Figure 3. Causes of fetal hypoxia and consequences in regard to placental morphology, 
such as enlargement of vascular surface and capillary dilatation [17] 
 
 
 
 
Gestational diabetes results in variances in uteroplacental circulation [17] and in 
contrast with normal pregnancy it leads to fetal vascular redistribution, alterations in 
uteroplacental circulation can be detected in case of pregnancies complicated by IUGR as 
well, which can be demonstrated by blood flow indices using 3-D technology [22, 23]. 
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3.2. IUGR 
The estimated fetal weight below the 10
th
 percentile for gestational age is considered 
growth restricted [24, 25]. The frequency of intrauterine restriction is 8-10% in Hungary [24]. 
This ratio indicates similar ascending tendency in our country, such as in other parts of the 
world [26]. Perinatal complications happen 3-4 times more frequently than in case of 
eutrophic newborns at the same gestational age. Nearly 50% of premature infants are retarded 
as well [24]. 30% of still-born have IUGR [7]. Therefore IUGR is a clinically significant 
perinatal problem [28, 29]. 
Clinical appearance of IUGR primarily depends on the GA of the pregnancy when the 
different inducing factors are present as well as on the duration of damage to the fetus. 
Reasons for development of IUGR can be maternal, fetal, uteroplacental or any other reasons 
[29] (see Table 1). The decline of adaptive capacity of the fetus causes circulatory 
redistribution for the good of substantial organs such as brain, heart and adrenal glands 
(„heart and brain sparing effect”) [30]. If the fetal circulation worsens further during 
pregnancy, the physiological compensatory mechanisms will be exhausted and hypoxic stress 
will be emerged eventuating in hypoglycemia, acidosis, thrombocytopenia and oliguria. The 
alteration of the uteroplacental circulation leads to fetal hypoxia, in consequence of which not 
only the pO2, but also the depot of glucose and glycogen will be reduced. Thus the fetal 
energy sparingly adapts to hypoxia and hypoglycaemia. The fetus stops or reduces weight-
gain, the fetal activity is impaired and the IUGR comes into existence. 
The main entity of IUGR development is characterized by the damage of the function 
of fetoplacental unit, which can have several effects including decrease of uteroplacental 
flow, insufficient metabolic process of the intervillous space and damage to the umbilical cord 
and fetal blood flow [29]. Reductions in uteroplacental blood flow and alterations in 
intervillous hemodynamics result from retained spiral arteriole contractility originating from 
inadequate remodelling by trophoblasts. Impairment in the development of placental vessels 
leads to diminution of fetal growth. The reduction in umbilical blood flow can be due to a 
decrease in uteroplacental blood flow, abnormal villous structure at the interface between the 
maternal and fetal circulation and primary abnormality in the umbilical-placental perfusion 
(see Figure 4) [30]. A decline in the number and surface area of the arterioles of the tertiary 
stem villi, a reduction in terminal capillary loops with elongated villi and a reduction in 
villous tree elaboration have been shown in IUGR [31, 32]. 
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Figure 4. The relationship between Doppler flow velocities of umbilical and uterine artery 
and placental morphology of villi [30] 
 
4. Aims of the investigation 
The aims of our study were as follows: 
 
4.1. GDM/T1DM 
1. To evaluate the placental 3-DPD indices in pregnancies complicated by the alteration 
of carbohydrate metabolism (GDM and T1DM pregnancies) in the second and third trimester. 
2. To observe the changes of 3-DPD indices by gestational age. 
3. To test the hypothesis whether there is an association between 2-D color Doppler 
indices (2-DCD) of umbilical/uterine arterial flow imaging and placental 3-DPD indices both 
in T1DM and GDM as well as in the control group. 
 
4.2. IUGR 
1. To evaluate the placental 3-DPD indices in pregnancies complicated by IUGR in the 
second and third trimester. 
2. To analyze the correlation between 2-DCD indices determined for conventional 
uterine/umbilical arterial flow imaging and 3-DPD indices in pregnancies complicated by 
IUGR. 
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3. To survey the effect of parity, gravidity and pregestational BMI on the alteration of   
vascularisation indices. 
4. To examine perinatal outcomes in pregnancies complicated by IUGR. 
 
5. Materials and methods 
A consecutive series of pregnant women was recruited for a case-control study at the 
Department of Obstetrics and Gynecology, Szeged, Hungary from 2011-2013. We received 
informed written consent from all participants.  
 
5.1. GDM/T1DM 
 The pregnancies were divided into two groups: I. non-pathological control group 
(n=113) and II. case group comprising pregnancies complicated by two subgroups of diabetes 
mellitus (DM) (n=99): II.a) DM (n=43) and II.b) GDM (N=56). GDM cases complied with 
White’s class A1-A2, while DM cases belonged to DM type I (T1DM) with a good glycemic 
control (HbA1c: 20-42 mmol/mol) corresponding to White’s class B-D [33]. No patient was 
classified in White’s class R, F, RF, G, H and T [33]. Table 3 contains the exclusion criteria. 
 
Table 3. Exclusion criteria of GDM/T1DM and IUGR 
- multiple pregnancy 
- enlarged (≥3mm) nuchal translucency from 11+0 to 13+6 weeks of gestation 
- fetal or neonatal structural or chromosomal anomaly 
- inadequate localization of the placenta (placenta previa)  
- posterior placenta (did not belong to the exclusion criteria of IUGR) 
- self-reported drugs, alcohol, caffeine or nicotine abuse 
- exposure to circulatory medication (oxerutins, calcium dobesilate)  
- not signing the consent form.  
- diabetes accompanied by another systemic disease  (autoimmune disease, vasculitis, 
haemophylia, thrombophylia, hypertension, HIV infection,  etc.)  
- diabetes mellitus (belonged to exclusion criteria of IUGR), abnormal HbA1c value 
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5.1.1. Diagnosis of GDM/T1DM 
According to the recommendation of American Diabetes Association, GDM is a 
pathological condition, in which women without previously diagnosed diabetes exhibit high 
blood glucose levels during pregnancy, irrespective of whether it is treated with diet or 
insulin, which disappears or maintains after pregnancy [17, 18]. Diagnostic criteria for DM 
and GDM are based on World Health Organisation (WHO)’s guidelines, which correlates 
with the guideline of Hungarian College of Obstetricians and Gynecologists [18].   
In our study oral glucose tolerance test (OGTT) was used between 24-28
th
 weeks of 
gestation for diagnosing diabetes. 75 grams of glucose solution was consumed by the 
pregnant woman after a fasting period of 8 hours.  
The glucose level in maternal serum (sample tube contains potassium oxalate and 
sodium fluoride/Na2 EDTA) samples was measured at the start (0 min) and after 2 hours [17, 
18]. Diagnostic criteria for GDM are set up, if a) the fasting blood glucose level is ≥ 7 mmol/l, 
or b) the fasting glucose is normal, but the postprandial 120-minute value is ≥7.8 mmol/l, or 
c) the random glucose level is ≥11.1 mmol/l which are measured twice [18, 34-36]. If women 
before subsequent pregnancy had been affected by DM, the OGTT was not performed, but 
dietary treatment was administered. High risk pregnancies for GDM (see Table 2) [33] were 
screened with OGTT between 12-16
th
 weeks of gestation, and if the result was below the 
limit, then OGTT was repeated between 24-28
th
 weeks of gestation. In our country the 
patients who do not have high risk for GDM are screened with OGTT when they are 24-28
th
 
weeks pregnant [17, 18, 37]. 
 
5.2. IUGR 
The pregnancies were divided into two groups: non-pathological control group (n=171) 
and IUGR group (n=52) [24]. The exclusion criteria can be found in Table 3. 
 
5.2.1. Diagnosis of IUGR 
  A fetus whose estimated weight is below the 10
th 
percentile for its gestational age is 
considered as a fetus with IUGR (Figure 5, 6) [24, 38].  
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Figure 5. WHO: Weight percentile chart (data). The weight percentile illustration is based on 
fetal weight equation proposed by Hadlock et al. [42]. 
 
 
 
Figure  6. WHO: Weight percentile chart (diagram). The weight percentile illustration is 
based on fetal weight equation introduced by Hadlock et al. [42]. 
 
 
 
  The term small for gestational age (SGA) defines an infant that has failed to achieve a 
weight threshold (10
th
 percentile). Using this threshold, 10 % of the normal population will be 
included by statistical definition and this group will comprise constitutionally small but 
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healthy babies. IUGR fetuses represent a subgroup of fetuses that have failed to reach their 
growth potential for various reasons. In other words, IUGR is the pathological counterpart of 
SGA [39]. 
The oldest of the clinical methods, namely abdominal palpation, is accomplished using 
the Leopold manoeuvres [40], but its ability to predict fetal weight is limited [41]. Abdominal 
palpation (measuring symphysis-fundal height) is a tool which raises suspicion of low birth 
weight. The most valuable method to define IUGR is the ultrasound examination. Parameters 
most commonly used for determining estimated fetal weight (EFW) by ultrasonography 
include biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) 
and femur length (FL) [42].  
 
5.3. Conventional two-dimensional (2-D) and color Doppler investigations 
The determination of GA was based on the first day of the last menstrual period and/or 
on ultrasound biometry (crown-rump length and biparietal diameter) at 10
th
 week of 
pregnancy. All patients were scanned in a semirecumbent position. An initial 2-D 
conventional study provided data about fetal position and presentation, body movements and 
fetal heart rate, placental localization and umbilical cord insertion. The factorial default 
setting "Obstetrics/2-3 trimester" was used in 2-D mode. The examination was followed by a 
fetal biometry to assess biparietal diameter, head circumference, abdominal circumference 
and femur length. Fetal weight was calculated by the formula B of Hadlock [42]. A 
conventional color Doppler study of umbilical and uterine arteries [43] were also performed 
and the flow S/D ratio and resistance index (RI) were calculated according to the formula 
RI=S–D/S, where S is the maximum systolic velocity and D is the minimum telediastolic 
velocity. Besides, we measured the pulsatility index (PI) with the help of the formula: PI=S-
D/mean velocity. The indices were read from the reports of the display of ultrasound machine. 
 
5.4. Three –dimensional (3-D) ultrasound evaluation of the placenta 
 3-DPD ultrasound as well as quantitative 3-DPD histogram analysis, quantitative and 
qualitative assessments of the vascularisation and blood flow of the placenta have become 
feasible as compared to 2-DCD imaging. 
 
5.4.1. Three-dimensional power Doppler (3-DPD) ultrasound 
3-DPD ultrasound can depict intraplacental vessel characteristics such as density of 
vessels, branching and changes in lumen [1, 44-47].  3-DPD ultrasound examination was 
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found to be more accurate than 2-D power Doppler (2-DPD) ultrasound examination for the 
detection of secondary and tertiary stem vessels in the placenta [46]. 
Total reduced placental vascularity and impaired budding of the villous circulation are 
predictive of those cases of IUGR not identified by either uterine or umbilical artery blood 
„flow velocity waveforms” [1]. This should be relevant in clinical practice, because 
incomplete placental development is generally associated with IUGR [44]. The sonographic 
presence of thick heterogeneous placenta is strongly associated with perinatal death, 
hypertensive disorders, IUGR, and preterm delivery [48]. 3-DPD ultrasound clearly shows 
reduced placental vascularity and impaired budding of the villous circulation in severe IUGR 
pregnancy with a thick heterogeneous placenta (Figure 7). 3-DPD ultrasound may be useful 
in the future for diagnosing impaired vascularity associated with IUGR pregnancies. 
3-DPD ultrasound plays an important role in the evaluation of vasa previa, it shows 
clearly a highly visualized placental chorioangioma and it is a useful technique to diagnose 
placenta accreta. Furthermore in monochorionic placenta vascular anastomosis (arterio-
arterial, arteriovenous) can be visualized in detail as well [49]. 
 
 
 
Figure 7. Multiplanar display of the thick heterogeneous placenta in a case of severe fetal 
growth restriction (<3 percentile) at 29 weeks of gestation 
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5.4.2. Quantitative three-dimensional power Doppler (3-DPD) histogram analysis 
3-D volume is constituted of small units of volume-„voxels”. Voxels contain all the 
information about grey and color intensity scale ranging from 0 to 100. According to these 
values, three power Doppler indices suitable for evaluating vessels and blood flow can be 
derived from this measurement system. These 3-DPD indices are utilized to assess placental 
perfusion, and it has been accepted that these indices potentially reflect to both uteroplacental 
and fetoplacental blood flow [45, 50, 51].  
The vascularisation index (VI), which refers to the color voxel/total voxel ratio, 
measures the number of color voxels in the studied volume and represents the blood vessels 
within the volume of interest, and expresses it as a percentage (vascularity). The flow index 
(FI) is the average color value of all the color voxels and it shows the average blood flow 
intensity from 0 to 100 (no unit). The vascularisation flow index (VFI), which refers to the 
weighted colour voxel/total voxel ratio, combines the information on vessel presence 
(vascularity) and amount of blood cells transported (no unit). The value is 0-100. [52, 53]. 
The assessment of placental perfusion using 3-DPD ultrasound examination is called 
‘placental vascular biopsy’ [52], ‘placental vascular sonobiopsy’ (PVS) [54], or ‘virtual 
placental biopsy’ [51]. There are different kinds of methods applying PVS. Vascularisation 
indexes can be determined in the whole placenta [55-57] (Figure 8), in 5 [58] (Figure 9) or 9-
12 [54] (Figure 10) different parts of the placenta and in a 3x3x3mm volume of the placenta 
at insertion of umbilical cord [52] (Figure 11). The VOCAL program calculates automatically 
the indices (VI, FI, VFI) from the acquired sample (Figure 12).  
 
Figure 8. Determination of placental indexes in the entire placenta by Rizzo et al., de Paula 
et al. and Pomorski et al.[55-57] 
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Figure 9. Determination of placental indexes in 5 different parts of the placenta by 
Guiot et al. [58] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Determination of placental indexes in 9-12 different parts of the placenta 
by Noguchi et al. [54] 
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Figure 11. Determination of placental indices by „Mercé-type sonobiopsy” [52] 
 
 
Figure 12. The results of histogram analysis of the sphere volume obtained are shown 
automatically on the screen (Mercé-type sonobiopsy) 
 
Despite its usefulness, one study has focused on 3-D examination of the placenta in DM 
so far [57]
 
and only quite a few studies in IUGR [54, 56, 58]. In 2012, Rizzo et al. performed 
3-DPD ultrasonography of the placenta at 11+0-13+6 weeks in 32 pregnancies complicated 
by T1DM. Placental volume and vascularisation indices were calculated in the whole placenta 
[55]. In 2008, Guiot et al [58] performed examinations on 45 gravidas between 23-37
th
 weeks 
of gestation, among which 15 pregnant women were enlisted in the group of physiological 
pregnancies and 30 pregnant women in the IUGR group. Placental vascularisation indices 
were assayed in 5 different parts of the placenta. In 2009, Noguchi et al [54] examined 221 
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placentas (normal group: 12-40 weeks of gestation, 208 pregnancies; IUGR group: 29-39 
weeks of gestation, 13 pregnancies). Placental indices were calculated in 9-12 parts of the 
placenta. In 2011, Pomorski et al [56] involved 120 pregnant women in their studies between 
22-42 gestational weeks (normal group: 100 gravidas, IUGR group: 20 gravidas). They 
measured the volume of the placenta and determined vascularisation indices in the whole 
placenta. 
 
5.5. Volume acquisition 
Acquisition of the images used for the determination of placental volume and 3-DPD 
indices was realized at the time of visit. All 3-D scans and the 2-D ultrasound measurements 
were achieved by Voluson 730 Expert ultrasound machine (GE Medical Systems, 
Kretztechnik GmbH&Co OHG, Austria) equipped with a multifrequency probe (2-5 MHz). 
Each sample was examined using 3-D rendering mode, in which the color and gray value 
information was processed and combined to give 3-D image (mode cent; smooth: 4/5; FRQ: 
low; quality: 16; density: 6; enhance: 16; balance: 150; filter: 2; actual power: 2 dB; pulse 
repetition frequency: 0.9) [37]. For laterally located placentas slight lateral inclination of the 
transducer was positioned to reach proper images. Power Doppler window (pulse repetition 
frequency at 900 Hz and wall filter of 50 Hz) was placed over the placenta mapping the 
vascular tree from basal to chorionic plates. We used fast low resolution acquisition to avoid 
any kind of artefacts. The 3-D static volume box was placed over the highest villous vascular 
density zone at umbilical cord insertion [53, 59]. The sweep angle was set at maximum 70 
degrees. Volume acquisition was made during a time interval varying from 5 to 15 seconds in 
the absence of fetal movements and with mother being as motionless as possible. Each image 
was recovered from the disk in succession for processing [53, 59]. During gestation we 
recorded one sample from each patient. 
 
5.6. Calculation of power Doppler (PD) Indices 
The stored volumes were further analyzed using the VOCAL program pertaining to the 
computer software 4-DView (GE Medical Systems, Austria, version 10.4). Each volume was 
recovered from the hard disk in succession and processed using the multiplanar system. The 
three planes of acquired placental volume were explored to localize the zone where the 
highest vascular density was found by PD mode [59].  The type of sonobiopsy (called 
“Mercé-type sonobiopsy”) that we used is a reproducible, validated method [53, 54, 57], and 
by obtaining a representative sample of the placental tree it is applicable throughout the whole 
25 
 
 
pregnancy in contrary to other methods, in which the entire placenta needs to be visualized 
[55]. 
PD technique shows high sensitivity, because it is based on amplitude instead of mean 
frequencies to depict the vascular tree [59]. Moreover, the colour mapping is independent of 
the angle of insonation and does not show ‘aliasing’. However, it is more sensible to patient 
movements, so the volumes should be acquired avoiding any probe or patient movements, 
otherwise artefacts could be present. Due to shortest possible time that was applied to acquire 
a placental volume (5 to 15 seconds), that sort of artefacts affecting visualisation was 
absolutely minimized [59]. We did not take the 3-DPD volume into consideration if motion 
artefact appeared and in these cases we repeated the acquisition again and again until we have 
obtained a clear view of 3-DPD volume, besides 4-D view program is not able to calculate the 
3-DPD indices (VI, FI, VFI) when an artefact is recorded. 
 
5.7. Statistics 
5.7.1. Statistical analysis methods in groups GDM/T1DM 
The statistical analysis was conducted with SPSS for Windows version 17.0 (SPSS 
Inc, Chicago, IL, USA). The continuous variables were expressed as median±standard 
deviation. Kruskal-Wallis tests were used for comparison of continuous variables depending 
on the three subgroups (T1DM versus (vs.) GDM vs. controls), whereas comparison between 
two subgroups (T1DM vs. GDM) was assessed with Mann-Whitney-U test. Univariate 
comparisons for categorical variables were assessed by χ2-tests. Linear regression coefficient 
values and equations depending on gestational age were also calculated for VI, FI, VFI 
indices both for diabetic and control groups. The distributions of placental indices (25th, 50th 
and 75th percentiles) according to GA were plotted and predictive values were also calculated 
for diabetic pregnancies. The association between placental 3-DPD indices and 2-DCD 
indices (RI and PI of umbilical and uterine arteries) was determined by Spearman’s rank 
correlations. 
 
5.7.2. Statistical analysis methods in group IUGR 
The statistical analysis was conducted with SPSS for Windows version 17.0 (SPSS Inc, 
Chicago, IL, USA). An analysis of variance (ANOVA) was carried out to examine the 
association of the 3-DPD indices with the gravidity, parity, and pregestational body mass 
index (BMI). The Mann–Whitney U test, the t test, and the z-score were used to compare 3-
DPD indices (VI, FI, VFI); estimated fetal weight, birth weight, and birth length; the mode of 
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delivery; the occurrence of intrauterine complications; the necessity of transfer to the neonatal 
intensive care unit; the Apgar scores at 1, 5, and 10 minutes; and the umbilical cord arterial 
pH between the IUGR group and the control group. p≤0.01 was considered statistically 
significant. A quantile regression method was used to investigate the relationship between 3-
DPD indices (VI, FI, VFI) and gravidity, parity, and pregestational BMI. The association 
between placental 3-DPD indices and 2-DCD indices (RI and PI of umbilical and uterine 
arteries) was determined by Spearman’s rank correlations.  
 
6. Results  
6.1. GDM/T1DM 
The characteristics of pregnancies are found in Table 4, which show no significant 
difference in control, T1DM and GDM groups by Kruskal-Wallis test (p>0.05). The 
ultrasound-derived estimated fetal weight was not distinguishable between the two diabetic 
subgroups in any logistic regression analysis in relation to GA and placental 3-DPD indices 
(p>0.05). 
 
Table 4. Pregnancy characteristics of each study group at ultrasound examination 
 GDM  (n=56) T1DM  (n=43) Control  (n=113) 
Maternal age 
(years) 
(mean±S.D.) 
 
33±5,1 
 
32±5 
 
30,7±5,4 
Weeks of 
gestation 
(mean±S.D.) 
 
30
+7±6+4 
 
31 ±7+4 
 
28
+4
 ±5+5 
Estimated fetal 
weight (gram) 
(mean±S.D.) 
 
1723±1007 
 
1737±1222 
 
1223±195,1 
GDM: gestational diabetes mellitus 
T1DM: diabetes mellitus type I 
S.D.: standard deviation 
 
Figure 13 a-c and Table 5 display the placental indices in the three study groups. 
Kruskal-Wallis tests showed that all three placental indices were significantly reduced among 
27 
 
 
diabetic pregnant women as compared to the control group (p<0.001 for each index). None of 
placental indices indicated significant difference between T1DM and GDM pregnancies 
(p>0.05). 
 
 
 
Figure 13.a. Flow index (FI) in GDM/T1DM and control group. Horizontal lines represent 
interquartile ranges with medians, whiskers represent smallest and largest values and º 
represents an outlier (control: 113 cases, GDM: 56 cases, T1DM: 43 cases) 
 
 
GDM: gestational diabetes mellitus 
T1DM: diabetes mellitus type I 
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Figure 13.b. Vascularisation index (VI) in GDM/T1DM and control group. Horizontal lines 
represent interquartile ranges with medians, whiskers represent smallest and largest values 
and º represents an outlier (control: 113 cases, GDM: 56 cases, T1DM: 43 cases) 
 
GDM: gestational diabetes mellitus 
T1DM: diabetes mellitus type I 
 
Figure 13.c. Vascularisation flow index (VFI) in GDM/T1DM and control group. 
Horizontal lines represent interquartile ranges with medians, whiskers represent smallest and 
largest values and º represents an outlier (control: 113 cases, GDM: 56 cases, T1DM: 43 
cases) 
 
GDM: gestational diabetes mellitus 
T1DM: diabetes mellitus type I 
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Multiple logistic regression analysis showed that the odds of GDM are increased at a 
higher GA [p<0.001, adjusted odds ratio (AOR): 1.1 (95% Confidence Interval (CI): 1.07-
1.16)] and a lower FI [p<0.001, AOR: 0.88 (95%CI: 0.85-0.93)], or at a higher GA and a 
lower VI [p<0.001, AOR: 0.83 (95%CI: 0.77-0.94)], or at a higher GA and a lower VFI 
[p<0.001, AOR: 0.63 (95%CI: 0.51-0.77)]. If all power Doppler indices are low [FI: p<0.001, 
AOR: 0.91 (95% CI: 0.87-0.94)]; [VFI: p<0.001, AOR: 0.64 (95% CI: 0.55-0.75)]; [VI: 
p<0.001, AOR: 0.83 (95% CI: 0.77-0.89)] during late pregnancy, then the odds of the fact 
that the pregnancy is complicated by any type of diabetes [p<0.001, AOR: 1.10 (95% CI: 
1.06-1.14)] is also significantly high. 
 
Table 5.  Placental Doppler indices of each study group 
 
GDM (n=56) T1DM
 
  (n=43) 
Control 
(n=113) 
p-value 
Vascularisation 
index 
(mean±S.D.) 
 
5,30±3,88 
 
4,81±3,72 
 
10,26±6,73 
 
<0,001 
Flow index 
(mean±S.D.) 
 
36,71±7,18 
 
36,86±10,44 
 
44,83±8,47 
 
<0,001 
Vascularisation 
flow index 
(mean±S.D.) 
 
2,12±1,58 
 
2,02±1,87 
 
4,94±3,73 
 
<0,001 
 
GDM: gestational diabetes mellitus 
T1DM: diabetes mellitus type I 
S.D.: standard deviation 
 
 The positive predictive reference values for VI, FI, and VFI in pregnancies 
complicated by diabetes are shown in Table 6. 
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Table 6.  Reference values for Flow Index, Vascularisation Flow Index and Vascularisation 
Index among mothers with (gestational) diabetes mellitus 
Gestational 
age (weeks) 
Flow Index Vascularisation Flow Index Vascularisation Index 
-S.D. 
Predicted 
value 
+S.D. -S.D. 
Predicted 
value 
+S.D. -S.D. 
Predicted 
value 
+S.D. 
12 39.06 40.65 42.24 2.32 2.76 3.2 5.93 6.21 6.49 
13 38.83 40.42 42.01 2.28 2.72 3.16 5.87 6.15 6.43 
14 38.6 40.19 41.78 2.24 2.68 3.12 5.81 6.09 6.37 
15 38.37 39.96 41.55 2.2 2.64 3.08 5.75 6.03 6.31 
16 38.14 39.73 41.32 2.16 2.6 3.04 5.69 5.97 6.25 
17 37.91 39.5 41.09 2.12 2.56 3 5.63 5.91 6.19 
18 37.68 39.27 40.86 2.08 2.52 2.96 5.57 5.85 6.13 
19 37.45 39.04 40.63 2.04 2.48 2.92 5.51 5.79 6.07 
20 37.22 38.81 40.4 2 2.44 2.88 5.45 5.73 6.01 
21 36.99 38.58 40.17 1.96 2.4 2.84 5.39 5.67 5.95 
22 36.76 38.35 39.94 1.92 2.36 2.8 5.33 5.61 5.89 
23 36.53 38.12 39.71 1.88 2.32 2.76 5.27 5.55 5.83 
24 36.3 37.89 39.48 1.84 2.28 2.72 5.21 5.49 5.77 
25 36.07 37.66 39.25 1.8 2.24 2.68 5.15 5.43 5.71 
26 35.84 37.43 39.02 1.76 2.2 2.64 5.09 5.37 5.65 
27 35.61 37.2 38.79 1.72 2.16 2.6 5.03 5.31 5.59 
28 35.38 36.97 38.56 1.68 2.12 2.56 4.97 5.25 5.53 
29 35.15 36.74 38.33 1.64 2.08 2.52 4.91 5.19 5.47 
30 34.92 36.51 38.1 1.6 2.04 2.48 4.85 5.13 5.41 
31 34.69 36.28 37.87 1.56 2 2.44 4.79 5.07 5.35 
32 34.46 36.05 37.64 1.52 1.96 2.4 4.73 5.01 5.29 
33 34.23 35.82 37.41 1.48 1.92 2.36 4.67 4.95 5.23 
34 34 35.59 37.18 1.44 1.88 2.32 4.61 4.89 5.17 
35 33.77 35.36 36.95 1.4 1.84 2.28 4.55 4.83 5.11 
36 33.54 35.13 36.72 1.36 1.8 2.24 4.49 4.77 5.05 
37 33.31 34.9 36.49 1.32 1.76 2.2 4.43 4.71 4.99 
38 33.08 34.67 36.26 1.28 1.72 2.16 4.37 4.65 4.93 
39 32.85 34.44 36.03 1.24 1.68 2.12 4.31 4.59 4.87 
40 32.62 34.21 35.8 1.2 1.64 2.08 4.25 4.53 4.81 
41 32.39 33.98 35.57 1.16 1.6 2.04 4.19 4.47 4.75 
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Figure 14. a-c present the placental 3-D Doppler indices in relation to GA in the 
control group versus diabetic cases. The linear regression equations for VI, FI, and VFI vs. 
GA among the control cases were as follows: FI=47.82+(-0.13*GA); r=0.123, p<0.001; 
VI=14.67+(-0.20*GA); r=0.288, p<0.001; VFI=7.44+(-0.11*GA); r=0.233, p<0.001. All 3-
DPD indices decreased slightly by GA. The linear regression equations were FI=43.41+(-
0.23*GA); r=0.182, p=0.07; VI=6.93+(-0.06*GA); r=0.012, p<0.25; VFI=3.24+(-0.04*GA); 
r=0.164, p=0.107 among diabetic pregnant women. 
 
 
 
Figure 14.a. Placental 3-D power Doppler indices in GDM/T1DM as well as in control 
group compared to gestational age: vascularisation index (♦: control group n=113, ■: 
GDM/T1DM group n=99) 
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Figure 14.b. Placental 3-D power Doppler indices in GDM/T1DM and control group 
compared to gestational age:  flow index (♦: control group n=113, ■: GDM/T1DM group 
n=99) 
 
 
Figure 14.c. Placental 3-D power Doppler indices in GDM/T1DM and control group 
compared to gestational age: vascularisation flow index. (♦: control group n=113, ■: 
GDM/T1DM group n=99) 
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The equations were not significantly different from each other in T1DM and GDM 
group and the parameters of equations were significantly different from the parameters of the 
control group.  
There were no associations between placental 3-DPD indices and 2-DCD indices (PI, 
RI of umbilical and uterine arteries) which were determined by Spearman’s rank correlations 
(p<0.01). The intraobserver errors were evaluated by repeated measurements of the 3-DPD  
indices at the initiation of the study. The intra-class correlation coefficients for all Doppler 
indices were excellent (0.99) for all indices. The difference between the mean difference (VI: 
0.04, FI: 0.09, VFI: -0.008) and zero was not significant for any 3-DPD index (p>0.05). 
 
6.2. IUGR  
A total of 223 women were enrolled: 171 were in the control group and 52 were in the 
IUGR group. Demographic and obstetric characteristics are demonstrated in Table 7. 
 
Table 7.  Demographic and obstetric characteristics 
a
 
 Control group 
(n=171) 
IUGR group 
(n=52) 
P 
value 
Age, y 31.0 (28–34) 30.0 (26–34) 0.1 
Pregnancy duration at the time of 
ultrasonographic examination, wk 
30.4 (19.0–37.0) 31.9 (24.1–37.6) 0.1 
Median length of pregnancy, wk 39.1 (38.1–40.0) 38.4 (37.3–39.1) 0.2 
Gravidity    
<3 123 (71.9%) 28 (53.8%) 0.01 
≥3 48 (28.1%) 24 (46.1%) 0.01 
Parity 
b
    
<3 87 (83.6%) 26 (76.4%) 0.01 
≥3 17 (16.4%) 8 (23.6%) 0.01 
Pre-pregnancy BMI 22.1 ± 2.5 21.9 ± 1.5 0.01 
Perinatal complications  12 (7.0) 12 (23.1) 0.01 
Neonatal care 13 (7.6) 16 (30.8) 0.01 
Cesarean delivery 45 (26.3) 31 (59.6) 0.01 
Apgar score    
1 min 8.9 ± 2.3 9.0 ± 1.4 0.12 
5 min 9.3 ± 1.3 9.7 ± 0.9 0.01 
10 min 9.5 ± 0.8 9.8 ± 1.0 0.01 
Birth length, cm 49.6 ± 2.45 46.5 ± 3.4 0.01 
Birth weight, g 3351.9 ± 522.4 2674.4 ± 752.1 0.01 
Umbilical cord arterial pH 7.2 ± 0.2 6.9 ± 1.6 0.01 
Placental location    
Anterior wall 97 (56.7) 29 (55.8) 0.23 
Posterior wall 74 (43.3) 23 (44.2) 0.22 
a
 Values are given as median (interquartile range), number (percentage), or mean ± S.D.b Data 
available for 104 participants in the control group and 34 in the IUGR group. IUGR:  intrauterine 
growth restriction, BMI: body mass index, wk: week, y: year 
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Placental location [(control: anterior wall: 97 (56.7%), p=0.23; posterior wall: 74 
(43.3%), p=0.22) vs. (IUGR: anterior wall: 29 (55.8%), p=0.23; posterior wall: 23 (44.2%) 
p=0.22)] and 1-minute Apgar score (mean ± S.D.) [control (8.9 ± 2.3) vs. IUGR (9.0 ± 1.4) 
p=0.12] did not differ significantly between groups. Gravidity [control: <3: 123 (71.9%), 
p=0.01, ≥3: 48 (28.1%), p=0.01) vs. IUGR: (<3: 28 (53.8%), ≥3: 24 (46.2%), p=0.01)], parity 
[control: (<3: 87 (83.6%), ≥3: 17 (16.4%), p=0.01) vs. IUGR: (<3: 26 (76.4%), ≥3: 8 
(23.6%), p=0.01)], pregestational BMI (mean ± S.D.) [control (22.1 ± 2.5) vs. (IUGR: 
(21.9 ± 1.5), p=0.01], umbilical cord artery pH (mean ± S.D.): [control (7.2 ± 0.2) vs. IUGR 
(6.9 ± 1.6), p=0.01.], and 5-minute and 10-minute Apgar scores (mean ± S.D.): [control 
(9.3 ± 1.3;  9.5 ± 0.8) vs. IUGR: (9.7 ± 0.9;  9.8 ± 1.0), p=0.01] did differ significantly. 
Women in the IUGR group had significantly lower 3-DPD index values (VI, FI, VFI) 
than did the control group [VI (median (interquartile range) (%): control: 10.1 (8.6-10.9) vs. 
IUGR: 3.7 (3.2-4.2), p=0.001; FI (median (interquartile range)): control: 45.1 (44.1-53.1) vs. 
IUGR: 40,0 (39.7-42.5), p=0.0012; VFI (median (interquartile range)): control: 4.8 (4.4-5.3) 
vs. IUGR: 2.2 (2.1-2.4), p=0.0001] (Figure 15. a-c). 
 
Figure 15. a. Vascularisation Index in IUGR and control groups (median, interquartile 
range, p=0,001) 
 
IUGR: intrauterine growth restriction 
VI: vascularisation index 
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Figure 15.b. Flow Index in IUGR and control groups (median, interquartile range, p=0,012) 
 
IUGR: intrauterine growth restriction 
FI: flow index 
 
 
Figure 15.c. Vascularisation Flow Index in IUGR and control groups (median, interquartile 
range, p=0.0001) 
 
IUGR: intrauterine growth restriction 
VFI: vascularisation flow index 
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Table 8 shows the comparison of the vascularisation indices among women with 
different gravidities, parities, and pregestational BMIs. Gravidity, parity, and pregestational 
BMI had no significant effect on VI, FI, VFI by quantile regression analyses (p>0.01), but 
there were significant differences in VI, FI, VFI between the control and IUGR group 
(p<0.01). 
Perinatal complications occurred among 12 (23.1%) neonates in the IUGR group and 12 
(7.0%) in the control group (p=0.01). Neonatal intensive care was needed for 16 (30.8%) 
infants in the IUGR group and 13 (7.6%) in the control group (p=0.01). Median length of 
pregnancy was 38.4
th
 weeks (interquartile range 37.3–39.1) in the study group and 
39.1
th
 weeks (interquartile range 38.1–40.0; p=0.2) in the control group. The mean birth 
weight was 2674.4 ± 752.1 g in the study group and 3351.9 ± 522.4 g in the control group 
(p=0.01). The mean birth length was 46.5 ± 3.4 cm in the study group and 49.6 ± 2.45 cm in 
the control group (p=0.01). The mean z-score for the estimated fetal weight in IUGR 
pregnancies measured from 30
th
 to 38
th
 weeks of pregnancy was –2.9, indicating that the 
estimated fetal weights in the IUGR group were below the average measured in the control 
group by nearly three times the standard deviation. There were no associations between 
placental 3-DPD indices and 2-DCD indices (RI and PI of umbilical and uterine arteries) 
which were laid down by Spearman’s rank correlations (p<0.01).   
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7. Discussion 
7.1. GDM/T1DM 
We found a negative correlation between 3-DPD indices and GA in normal 
pregnancies. The declining tendency of 3-DPD indices was more remarkable in diabetic 
pregnancies. The unaffected cases had constant values of 3-DPD indices. The control group 
and the diabetic groups had overlaps of VI, FI, VFI values; hence 3-DPD indices are not 
diagnostic in diabetes. In a previous study by de Paula et al. [57] all placental vascular 
indices showed constant values, while increased volume expansion of placenta was observed 
in connection with GA.
 
In diabetes the placental vascular alteration is a consequence of 
change in maternal glucose metabolism [17, 61]. 
The quantitative changes in the vascular tree in the placenta in pregnancies complicated 
by GDM/T1DM are not well defined. Decreased placental VI, VFI in diabetes could be 
associated with down-regulated angiogenesis, diminished number of arterioles and the 
hypertrophic wall of these vessels [17]. The depressed FI might represent narrower inner 
vascular diameter [17, 61, 62]. 
In contrast to our results, a preceding article by Rizzo et al. [55] reported an increased 
placental circulation in diabetic pregnancies from 11
th
 week until the end of 13
th
 week of 
gestation, and a poor glycemic control was associated with higher placental 3-DPD indices. 
The possible explanation for this paradox could be that the distinct placental changes 
associated with diabetes mellitus depend on the gestational period. In the first trimester the 
high glucose level triggers vasculogenesis, but vasculopathy is not present yet [17]. In later 
stage of pregnancy the vasculopathy destroys the blood flow in placenta, especially if poor 
glycemic control exists. Reasons for reduced placental blood flow (FI) in diabetes are: 
inadequate opening of spiral arteries, acute atherosis and reduction in intervillous space 
volume because of edema and higher number of bulbous villi [17, 61]. GDM correlates to 
diminished branching, attenuated coiling, mitigated vascular diameters. The alteration of 
placental vasculature leads to diminished function of placenta [17, 61]. Since in GDM/T1DM 
the volume and weight of placenta increases (the placental parenchymal and villous tissue 
content is higher than in non-diabetic normal pregnancies), VI is proportionally reduced 
scaled to volume unit. 
The uteroplacental circulation can be detected by flowmetry of the umbilical and 
uterine arteries. Our study confirms the results of other research groups [63, 64] referring to 
their statements that GDM does not induce changes in umbilical and uterine circulation. In 
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diabetes, increased blood flow resistance of the umbilical artery is just a late pathognomonic 
sign of ischemic vascular changes in placenta [62, 65], therefore we added the analysis of the 
placental microcirculation to the conventional indirect uteroplacental sonographic 
examination. 
There are some available methods reported in the literature on measuring placental 
vascular flow [52-55, 59]. Our study was designed based on a literature search for this issue 
and our aim was to find a technique, which is applicable even if the whole placenta can not be 
visualized and irrespectively of the placental volume it can be used throughout the whole 
pregnancy. The “Mercé-type sonobiopsy” [55] was applied in our study as a well-defined, 
validated method [66], in which both the intraobserver and interobserver errors are low [52]. 
This method can be used not only in the first trimester, when the overwhelming majority of 
the abnormalities in high-risk pregnancies has not been developed yet, but also in the second 
and third trimester. 
The studies about reproducibility demonstrated that the measurement of placental 
microcirculation by sonobiopsy can be appropriate [55, 66] for opting for measuring placental 
indices for a long time-period (between 10
 
and 41 weeks of gestation). The umbilical cord 
insertion can be visualized until the end of pregnancy. From the early second trimester on it is 
impossible to visualize the placenta completely on the posterior wall that is why we excluded 
the cases with posterior placenta. In addition, the growth of the fetal skeleton reduces the 
effect of ultrasound examination. 
Pregnant women with DM in our study did not have any other microvascular diseases 
such as retinopathy or nephropathy, though fetal vessels of placenta showed dramatic changes 
in VI, FI and VFI. This assumes, that placental microvascularisation in diabetes is under 
control of fetal circulation factors as well [67]. 
In our study, only the most vascularised placental region (the site of umbilical cord 
insertion) was measured correlated to a standard volume unit. We applied sonobiopsy as the 
most accurate measurement method concerning vascularisation [53, 59]. Placental 3-DPD 
indices, measured by sonobiopsy clearly point to a decreasing tendency in regard to 
increasing GA in diabetic mothers. In addition, our measurements demonstrate that the 
placental region close to the umbilical cord insertion has constant vascularisation during 
normal pregnancy. However, significant difference can not be observed between cases when 
diabetes has been developed prior to and during mid as well as late pregnancy. 
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7.2. IUGR 
We found that 3-DPD indices were significantly decreased in the IUGR pregnancies 
compared to the normal pregnancies.  There are some examples in the international literature 
that the placenta was examined by 3-DPD technique; however, the vast majority of the 
authors have only analyzed the changes in placental vascularisation [54, 56, 58] in IUGR, 
while we investigated the influence of 3-DPD indices on perinatal outcome as well. In 
addition, we applied a technique which is adequately reproducible until the end of the 
gestation period. 
Ultrasound plays an important role in diagnosis of IUGR. Parameters most commonly 
used for estimating fetal weight by ultrasonography include BPD, HC, AC and FL [42]. A 
reduced AC established by ultrasonographic evaluation is reported to be the most sensitive 
biometric measurement in predicting IUGR. An AC within the normal range reliably excludes 
IUGR with a false-negative rate of less than 10% [69].  In the most cases of IUGR we can 
find decreased amniotic fluid volume [70]. Oligohydramnios is considered to be present when 
the largest vertical pocket of amniotic fluid is less than 2 cm or the amniotic fluid index (AFI) 
is less than 5 cm. This index is the sum of the vertical amniotic fluid pocket in the 4 
abdominal quadrants [71, 72]. Doppler impedance measurement of umbilical and uterine 
artery is well suited to be a pivotal test in the management of IUGR fetus. If placental failure 
is the cause of intrauterine restriction, we can measure high impedance in umbilical and 
uterine arteries and notch in uterine artery [30]. Doppler examinations of the fetal circulation 
have the potential to reduce perinatal death and overtreatment such as unnecessary preterm 
labour induction [73-75]. The use of 3-D ultrasonography may increase diagnostic precision 
in the estimation and detection of fetal malformations [76]. 
Guiot et al [58] determined indices at 5 different places on the placenta. Noguchi et al 
[54] examined the entire placenta attached only to the anterior wall. Their testing method was 
to average the results of 9-12 sampling spheres by sonobiopsy. They investigated the 
vascularisation of the entire placenta, and neither the sampling volume nor the number of 
sampling spheres was standardized. Samples from barely vascularised edges and better 
vascularised centre parts were averaged, which may have led to significantly modified 
statistics. In 2009 de Paula et al [57] measured the vascularisation of the placenta as a whole, 
while Mercé et al [59] examined a 3x3x3mm volume part of the placenta directly at the 
adhesion of the umbilical cord, which is the most vascularised portion of the placenta (Mercé-
type sonobiopsy). We applied this technique for our examinations, which was necessary 
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because the entire placenta is difficult to visualize in the third trimester, especially when it 
adheres to the back wall of the uterus. The method is well standardized and reproducible, and 
intra- and inter-observer errors are also infrequent [68]. There is a debate over the normal 
reference range of placental indices established by various authors. Our evaluation verifies the 
results of the following authors: Guiot [58] and de Paula [57]. They found placental indices 
constant throughout the pregnancy. A possible explanation for the discrepancy noted above 
between the results of different authors is the diverse measuring technique, low case number, 
and the unpublished volumes and standardized settings of the ultrasound equipment. 
In our prospective study focusing on the determination of placental vascularisation 
indices (VI, FI, VFI) using Mercé-type sonobiopsy, we experienced that placental 
vascularisation is lower in the case of IUGR pregnancies compared to normal pregnancies, 
which supports the results of Pomorski et al, Noguchi et al and Guiot et al [54, 56, 58]. 
Placental PD vascularisation indices significantly decline compared to the control group. 
We did not find a significant discrepancy with regard to maternal age or gestational age 
at the time of examination between the IUGR and the control group; thus maternal age had no 
influence on the condition of arteries or on angiogenesis during pregnancy. Placental 
vascularisation indices are more or less constant during pregnancy [57, 58, 77]. The frequency 
of Cesarean section was significantly higher in the case group compared to the control group. 
Growth-restricted infants respond sensitively to stress during labour and tolerate vaginal 
delivery badly; thus Cesarean section is performed more frequently. In our study gestational 
and maternal age in the two groups had no influence on placental vascularisation indices. 5-
minute and 10-minute Apgar scores showed significant differences with regard to VI, FI and 
VFI, which can be explained by the poor postnatal adaptation of the infant restricted in the 
uterus. Complications, such as hypothermia, hypoglycemia, polycythemia, hyperviscosity and 
breathing problems emerge, and neonatal intensive care is more often needed compared to 
infants in the control group. The decrease in vascularisation indices is significant; the value of 
VFI, which is the most sensitive factor in indicating complications, is particularly predictive. 
However, we recommend the use of FI screening, since this parameter is minimally 
influenced by other factors, such as equipment settings. FI has the lowest coefficient of 
variation and intra-/inter-observer errors in measurements. 
Our study confirms statements made in a previous article [78] that there is no 
significant discrepancy between the location of the placenta and placental 3-DPD indices. 
Guimarães Filho HA et al [78] examined 283 women between 26-35th weeks of pregnancy 
and monitored the effect of the position of the placenta on the change of placental 
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vascularisation indices. The results of their research revealed that there is no significant 
coherence between FI, VI, VFI and the position of the placenta. We excluded placental 
adhesion anomalies and morphological disorders, because insufficient circulation may occur 
from the beginning of this type of pregnancy which could have falsely influenced our results, 
as indicated in a review article by Srividhya S et al. [29]. 
During our examinations we aimed at using an appropriately validated and 
reproducible method, which could be adopted in maternal care as a routine. Previously 
published methods cannot be applied comprehensively in general maternal care, partly 
because sampling volumes [57, 58] as well as the place and number of sampling [56] were not 
standardized; moreover, they are connected to the visualization of the entire placenta [54, 56, 
58], which can only be realized in selected cases, since it is not possible to visualize the whole 
placenta in the third trimester. 
We think that the machine settings could significantly influence comparisons of study 
findings, though they do not affect the observation of changes of 3-D vascular indices during 
pregnancy and the differences in case-control studies [54, 56, 58]. In conclusion, the main 
message of our study is that differences in placental vascular flow indices between normal 
and IUGR pregnancies can easily be established and not biased by our results. Therefore, we 
used standard machine settings. Volume acquisition was done during a time interval varying 
from 5 to 15 seconds lacking fetal motion and with the mother remaining as motionless as 
possible to prevent the display of any sort of artefacts. 
Our results confirm the hypothesis that there is a strong correlation between the 
deterioration of placental vascularisation and perinatal outcomes in pregnancies complicated 
by IUGR. We strongly consider the method of vascular sonobiopsy of the placenta 
beneficiary and applicable in monitoring patients so as to reduce the rate and range of 
perinatal complications. This may become a relevant method in ultrasound examinations; 
however, it is important to emphasize the recommendation that a therapeutic conclusion may 
only be drawn when it is based on a complete clinical background. 
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8. Conclusion 
A significant reduction in placental 3-DPD indices could be measured in pathological 
pregnancies (diabetic and growth restricted) applying 3-D sonobiopsy, which is a valid 
alternative for evaluation of the placental vascular tree when visualization of the entire 
placenta is not feasible. The evaluation of altered placental vascularisation by measurement of 
3-DPD indices (VI, FI, VFI) could be useful in checking the pathological pregnancies, 
however further studies on association between other pregnancy characteristics and 3-DPD 
indices are necessary in order to evaluate the usefulness of this method in screening 
complications of pathological pregnancies.  
In the future we would like to continue our research on this method, to develop and 
promote the accessibility of this method in clinical centres, but later in county hospitals as 
future screening centres as well and to make the possibilities of conventional identification of 
risk-pregnancies complete. Therefore we can affirm with certainty that after the evaluation of 
the findings and the adaptation of this method to the routine screening practice, we would 
improve the perinatal outcomes regarding morbidity and mortality. Our study group wishes to 
contribute to the creation of these potential facilities and I hope that based upon our research 
results this screening method will once become part of the pregnancy-care protocol. If we had 
the opportunity to accomplish this method in Hungary, we would be pioneers in the 
methodology and quality level of pregnancy care in Central and Eastern Europe. 
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9. The new results of the thesis 
 
1. The placental 3-DPD indices are nearly constant in normal pregnancies. 
2. The placental 3-DPD indices are significantly decreased in GDM/T1DM.  
3. None of placental indices showed significant difference between T1DM and GDM 
pregnancies. 
4. The placental 3-DPD indices are influenced by GA in GDM/T1DM pregnancies. 
5. The placental 3-DPD indices are significantly reduced in IUGR pregnancies. 
6. The placental 3-DPD indices are not influenced by maternal age, gravidity, parity, 
pregestational BMI and placental localization in IUGR pregnancies. 
7. There is a connection between 3-DPD indices and perinatal outcome. 
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